Telix Pharmaceuticals Ltd
Telix Pharmaceuticals Ltd is an Australia-headquartered biopharmaceutical company that develops and commercializes radiopharmaceuticals for oncology and rare disease applications. Its business combines marketed diagnostic products with a clinical-stage pipeline spanning precision imaging agents and targeted therapeutic candidates, supported by operations across North America, Europe, Latin America and Asia-Pacific.
Fiscal year 2025 · change from previous year
Development 2022–2025
Business
Share of revenueApproved radiopharmaceutical imaging kits used to prepare diagnostic agents for prostate cancer imaging.
Targeted radionuclide therapy candidates in late-stage development for cancer treatment.
Follow-on imaging agents in development for additional oncology indications.
Discovery, clinical development and regulatory work supporting the radiopharmaceutical pipeline.
Customers
Telix sells primarily into hospitals, imaging centers and nuclear medicine providers that use radiopharmaceuticals in cancer diagnosis and treatment. It also serves clinicians and treatment networks in oncology and related rare disease settings where targeted imaging or therapy can improve patient selection and care pathways.
Buy commercial imaging kits for prostate cancer diagnosis and staging.
Use Telix products to prepare and administer radiopharmaceutical diagnostics.
Adopt imaging and therapy products that support patient selection and treatment planning.
Participate in trials of Telix's therapeutic and next-generation imaging pipeline.
Purchase products that improve precision diagnosis and targeted treatment workflows.
Strategy
Telix's strategy centers on expanding commercial adoption of its prostate cancer imaging franchise while advancing follow-on imaging agents and therapeutic radiopharmaceuticals. It is also building manufacturing, isotope production and distribution infrastructure so it can support broader global launches and reduce execution risk across its portfolio.
The marketed imaging portfolio anchors revenue and establishes clinical relationships in nuclear medicine.
Late-stage assets can broaden the business from diagnostics into treatment and increase long-term value.
Reliable local production is critical in radiopharmaceuticals because isotopes and logistics constrain commercialization.
Geography
Telix is headquartered in Melbourne, Australia, and operates internationally across the United States, United Kingdom, Brazil, Canada, Europe and Japan. Its commercial footprint is important because radiopharmaceutical products depend on regulated manufacturing, isotope supply and local market access for launches and distribution.
Risks
Telix is exposed to regulatory, clinical and commercialization risk because much of its value depends on approval, launch and adoption of radiopharmaceutical products. It also faces operational risk from isotope supply, manufacturing scale-up and integration of global infrastructure, while competition in oncology imaging and therapy can pressure market access and execution.
- Supply chain and isotope riskImpact: HighLikelihood: High
Radiopharmaceuticals depend on specialized raw materials, isotope production and time-sensitive logistics.
Exposure: Manufacturing network and product distribution
- Regulatory approval riskImpact: HighLikelihood: Medium
The company relies on product approvals to convert pipeline assets into commercial revenue.
Exposure: Follow-on imaging agents and therapeutic pipeline
- Clinical development riskImpact: HighLikelihood: Medium
Late-stage therapeutic candidates may fail in pivotal trials or produce weaker-than-expected data.
Exposure - Commercial adoption riskImpact: MediumLikelihood: Medium
Demand depends on hospital workflows, reimbursement and physician uptake in nuclear medicine.
Exposure: Illuccix® and Gozellix®
Accounting
Judgemental itemsCommercial imaging products may involve timing differences between shipment, preparation and end-user consumption.
Impact: Can shift reported revenue between quarters.
Acquisitions and pipeline assets require ongoing valuation and impairment testing.
Impact: Could create material non-cash charges if product prospects change.
Clinical-stage programs require judgment on whether costs are expensed or capitalized.
Impact: Affects operating results and asset balances.
Similar listed companies
Publicly listed companies with a comparable business focus.
Radiopharm Theranostics Ltd
RDPTF · Pharmaceutical Preparations
Radiopharm Theranostics Ltd is an Australia-based clinical-stage radiopharmaceutical company developing diagnostic and therapeutic products for cancer.
Radnostix Inc
INIS · Industrial Instruments For Measurement, Display, and Control
RADNOSTIX INC is part of a U.S.-based nuclear medicine and isotope business that manufactures calibration and reference standards, radiochemical products, and cobalt-based source products.
GENELUX Corp
GNLX · Pharmaceutical Preparations
GENELUX Corp is a U.S.-based clinical-stage biopharmaceutical company focused on developing oncolytic vaccinia virus immunotherapies, led by its Olvi-Vec program.
Agentix Corp.
AGTX · Biological Products, (No Diagnostic Substances)
Janux Therapeutics, Inc.
JANX · Pharmaceutical Preparations
Janux Therapeutics is a clinical-stage biopharmaceutical company developing cancer immunotherapies built on its proprietary TRACTr, TRACIr, and ARM platforms.
ALX Oncology Holdings Inc
ALXO · Pharmaceutical Preparations
ALX Oncology Holdings Inc is a clinical-stage biotechnology company developing immuno-oncology therapies for cancer, headquartered in South San Francisco, California.
Last updated: 28/09/2026